Celldex Therapeutics Announces Proposed Public Offering of Common Stock
February 24 2015 - 4:00PM
Celldex Therapeutics, Inc. (Nasdaq:CLDX) today announced that it is
offering 7.25 million shares of its common stock in a proposed
underwritten public offering. The offering is subject to market
conditions and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering. The shares will be issued pursuant to a prospectus
supplement to be filed as part of a shelf registration statement
filed with the Securities and Exchange Commission (SEC) on Form
S-3.
Jefferies LLC and Leerink Partners LLC are acting as the joint
book-running managers and underwriters for the proposed offering
and Guggenheim Securities, LLC is acting as a lead manager in the
offering.
A shelf registration statement relating to the shares was filed
with the SEC and is effective. A preliminary prospectus supplement
related to the offering will be filed with the SEC and will be
available on the SEC's website located at http://www.sec.gov.
Copies of the preliminary prospectus supplement and the
accompanying prospectus relating to this offering may be obtained
from Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, 2nd Floor, New York, NY, 10022, by
telephone at 877-547-6340 or by email at
Prospectus_Department@Jefferies.com or from Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, by telephone at 800-808-7525 ext. 6142 or by
email at Syndicate@Leerink.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of
any such state or other jurisdiction.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address
devastating diseases for which available treatments are inadequate.
Our pipeline is built from a proprietary portfolio of antibodies
and immunomodulators used alone and in strategic combinations to
create novel, disease-specific therapies that induce, enhance or
suppress the body's immune response.
Safe Harbor Statement Under the Private Securities
Litigation Reform Act of 1995: This announcement contains
"forward-looking statements," including statements relating to
Celldex's expectations regarding the completion, timing and size of
the proposed public offering. These statements are subject to
significant risks and uncertainties; actual results could differ
materially from those projected and Celldex cautions investors not
to place undue reliance on the forward-looking statements contained
in this release. These risks and uncertainties include, without
limitation, risks and uncertainties related to whether or not
Celldex will be able to raise capital through the sale of shares of
its common stock, the final terms of the proposed offering, market
and other conditions, and the satisfaction of customary closing
conditions related to the proposed public offering . There can be
no assurance that Celldex will be able to complete the public
offering on the anticipated terms, or at all. Risks and
uncertainties relating to Celldex and its business can be found in
the "Risk Factors" section of Celldex's Form 10-K, filed with the
SEC on February 24, 2015, and in the preliminary prospectus
supplement and related prospectus related to the proposed offering
to be filed with the SEC. Celldex undertakes no duty or obligation
to update any forward-looking statements contained in this release
as a result of new information, future events or changes in
Celldex's expectations.
CONTACT: Company Contact:
Sarah Cavanaugh
Vice President of Investor Relations &
Corp Communications
Celldex Therapeutics, Inc.
(781) 433-3161
scavanaugh@celldex.com
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celldex Therapeutics (NASDAQ:CLDX)
Historical Stock Chart
From Apr 2023 to Apr 2024